CD4 and neoplasm: Hamada16 has also reported that TIL-present tumor immunity in the microenvironment subtypes of colorectal cancer are associated with better responsiveness to cancer immunotherapy, and low CD4+ and CD8+ TIL counts have also been found to predict extremely poor HCC-specific survival17.